NO873513L - Nye applikasjonsformer for alfa-interferoner. - Google Patents
Nye applikasjonsformer for alfa-interferoner.Info
- Publication number
- NO873513L NO873513L NO873513A NO873513A NO873513L NO 873513 L NO873513 L NO 873513L NO 873513 A NO873513 A NO 873513A NO 873513 A NO873513 A NO 873513A NO 873513 L NO873513 L NO 873513L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- acid
- interferons
- eye
- application forms
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 28
- 108010050904 Interferons Proteins 0.000 title claims description 28
- 229940047124 interferons Drugs 0.000 title claims description 18
- 229940079322 interferon Drugs 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 230000002378 acidificating effect Effects 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 9
- -1 aliphatic alcohols Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000003708 ampul Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000003860 storage Methods 0.000 description 10
- 239000003381 stabilizer Substances 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- CDZHZLQKNAKKEC-UHFFFAOYSA-N [bis(hydroxymethylamino)methylamino]methanol Chemical compound OCNC(NCO)NCO CDZHZLQKNAKKEC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863628468 DE3628468A1 (de) | 1986-08-21 | 1986-08-21 | Neue applikationsformen fuer (alpha)-interferone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO873513D0 NO873513D0 (no) | 1987-08-20 |
| NO873513L true NO873513L (no) | 1988-02-22 |
Family
ID=6307914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO873513A NO873513L (no) | 1986-08-21 | 1987-08-20 | Nye applikasjonsformer for alfa-interferoner. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4824674A (fi) |
| EP (1) | EP0258683A3 (fi) |
| JP (1) | JPS6351338A (fi) |
| KR (1) | KR880002541A (fi) |
| AU (1) | AU590958B2 (fi) |
| CA (1) | CA1313131C (fi) |
| DE (1) | DE3628468A1 (fi) |
| DK (1) | DK434087A (fi) |
| FI (1) | FI89007C (fi) |
| IL (1) | IL83585A0 (fi) |
| NO (1) | NO873513L (fi) |
| NZ (1) | NZ221497A (fi) |
| PT (1) | PT85561B (fi) |
| ZA (1) | ZA876166B (fi) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| GB8813032D0 (en) * | 1988-06-02 | 1988-07-06 | Boehringer Ingelheim Int | Antiviral pharmaceutical composition |
| DE3826055A1 (de) * | 1988-07-30 | 1990-02-01 | Boehringer Mannheim Gmbh | Mit reagenz abloesbar impraegnierte traegermatrix |
| JPH07501320A (ja) * | 1991-10-11 | 1995-02-09 | ギリーズ，マーク・セドリック | インタ−フェロン・アルファによる眼線維症の治療 |
| US5863530A (en) * | 1991-10-11 | 1999-01-26 | Spruson & Ferguson | Treating ophthalmic fibrosis using interferon-α |
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| DE19549506C2 (de) * | 1995-03-07 | 1998-07-30 | Richard Prof Dr Sueverkruep | Darreichungsform zur äußerlichen Applikation und Verfahren zur Herstellung derselben |
| WO1999066906A1 (en) * | 1998-06-22 | 1999-12-29 | Unihart Corporation | Sticking plaster for controlled release of natural interferon |
| US20030206945A1 (en) * | 2000-12-20 | 2003-11-06 | Giulio Tarro | Sticking plaster for controlled release of natural interferon |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| WO2003047470A2 (en) | 2001-12-04 | 2003-06-12 | Discure Ltd. | Cushion bearing implants for load bearing applications |
| EP2787007A3 (en) | 2010-11-08 | 2015-03-11 | F. Hoffmann-La Roche AG | Subcutaneously administered ANTI-IL-6 receptor antibody |
| WO2014184243A1 (en) * | 2013-05-16 | 2014-11-20 | Universiteit Antwerpen | Thermolabile drug release formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1055896A (en) * | 1963-12-10 | 1967-01-18 | Glaxo Lab Ltd | Silica adsorbents in interferon purification and/or concentration |
| DE2017373A1 (de) * | 1969-04-15 | 1971-04-22 | Orsymonde S A , Paris | Lyophihsierte Produkte und Ver fahren zu ihrer Herstellung |
| SE374272B (fi) * | 1973-08-31 | 1975-03-03 | D A Safwat | |
| US3932617A (en) * | 1974-05-24 | 1976-01-13 | The Upjohn Company | Interferon induction |
| US4357142A (en) * | 1980-07-18 | 1982-11-02 | Akzona Incorporated | Glass support coated with synthetic polymer for bioprocess |
| US4363634A (en) * | 1980-07-18 | 1982-12-14 | Akzona Incorporated | Glass support coated with synthetic polymer for bioprocess |
| US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| JPS5821691A (ja) * | 1981-07-29 | 1983-02-08 | Mochida Pharmaceut Co Ltd | α−及びβ−インタ−フェロンの精製方法 |
| DE3262575D1 (en) * | 1981-12-23 | 1985-04-18 | Schering Corp | Stabilised interferon formulations and their preparation |
| JPS59181224A (ja) * | 1983-03-29 | 1984-10-15 | Sumitomo Chem Co Ltd | 安定なインタ−フエロン製剤の製法 |
| US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
| DE3513288A1 (de) * | 1985-04-13 | 1986-10-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Verfahren und vorrichtung zur beaufschlagung von augenstaebchen mit wirkstoffloesungen oder -suspensionen |
-
1986
- 1986-08-21 DE DE19863628468 patent/DE3628468A1/de not_active Ceased
-
1987
- 1987-08-08 EP EP87111493A patent/EP0258683A3/de not_active Withdrawn
- 1987-08-19 IL IL83585A patent/IL83585A0/xx unknown
- 1987-08-19 CA CA000544820A patent/CA1313131C/en not_active Expired - Fee Related
- 1987-08-19 NZ NZ221497A patent/NZ221497A/xx unknown
- 1987-08-20 ZA ZA876166A patent/ZA876166B/xx unknown
- 1987-08-20 PT PT85561A patent/PT85561B/pt not_active IP Right Cessation
- 1987-08-20 NO NO873513A patent/NO873513L/no unknown
- 1987-08-20 FI FI873593A patent/FI89007C/fi not_active IP Right Cessation
- 1987-08-20 JP JP62207341A patent/JPS6351338A/ja active Pending
- 1987-08-20 DK DK434087A patent/DK434087A/da not_active Application Discontinuation
- 1987-08-20 KR KR870009090A patent/KR880002541A/ko not_active Ceased
- 1987-08-21 US US07/088,187 patent/US4824674A/en not_active Expired - Fee Related
- 1987-08-21 AU AU77307/87A patent/AU590958B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA1313131C (en) | 1993-01-26 |
| ZA876166B (en) | 1989-05-30 |
| JPS6351338A (ja) | 1988-03-04 |
| DK434087D0 (da) | 1987-08-20 |
| KR880002541A (ko) | 1988-05-09 |
| FI89007B (fi) | 1993-04-30 |
| PT85561B (pt) | 1990-05-31 |
| FI873593L (fi) | 1988-02-22 |
| AU590958B2 (en) | 1989-11-23 |
| DE3628468A1 (de) | 1988-03-03 |
| DK434087A (da) | 1988-02-22 |
| US4824674A (en) | 1989-04-25 |
| PT85561A (de) | 1987-09-01 |
| FI873593A0 (fi) | 1987-08-20 |
| IL83585A0 (en) | 1988-01-31 |
| AU7730787A (en) | 1988-02-25 |
| EP0258683A3 (de) | 1988-09-07 |
| NZ221497A (en) | 1990-04-26 |
| FI89007C (fi) | 1993-08-10 |
| NO873513D0 (no) | 1987-08-20 |
| EP0258683A2 (de) | 1988-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11066458B2 (en) | VEGF antagonist formulations suitable for intravitreal administration | |
| ES2153385T5 (es) | Composicion acuosa a base de hormona del crecimiento humana. | |
| CA2962480C (en) | Recombinant fusion protein formulation | |
| US9511116B2 (en) | Stable MIA/CD-RAP formulation | |
| PL184823B1 (pl) | Preparat do przechowywania substancji biologicznie aktywnych oraz sposób wytwarzania preparatu do przechowywania substancji biologicznie aktywnych | |
| FI89007C (fi) | Foerfarande foer framstaellning av nya applikationsformer foer -interferon | |
| EP3199555B1 (en) | Recombinant fusion protein formulation | |
| JPH01121223A (ja) | 生長因子を含有する安定な凍結乾燥した配合物 | |
| JP7855655B2 (ja) | コラゲナーゼ製剤およびその製造方法 | |
| JP6996713B2 (ja) | チモシンベータ４を含む眼科用製剤の製造方法 | |
| JPH08502722A (ja) | Ｉｌ−６含有薬剤組成物 | |
| JP3100058B2 (ja) | 線維芽細胞成長因子を含む安定な医薬組成物 | |
| NO324692B1 (no) | Engangs-sproyte | |
| PT86032B (pt) | Processo para a preparacao de um liofilizado de ifosfamida | |
| CN100553674C (zh) | 一种重组人甲状旁腺激素(1-84)药物组合物及其制备方法 | |
| EP3092009B1 (en) | Lyophilized mesna compositions | |
| US20040005310A1 (en) | Method for reconstituting lyophilized proteins | |
| EP4727582A1 (en) | Method for producing a lyophilized composition comprising polyclonal igm and composition obtained | |
| DK142420B (da) | Fremgangsmåde til fremstilling af i det væsentlige krystallinsk natriumcephalotin. |